In the past week, TECH stock has gone up by 3.33%, with a monthly gain of 2.38% and a quarterly plunge of -4.42%. The volatility ratio for the week is 3.08%, and the volatility levels for the last 30 days are 2.95% for Bio-Techne Corp The simple moving average for the last 20 days is 1.07% for TECH stock, with a simple moving average of 0.87% for the last 200 days.
Is It Worth Investing in Bio-Techne Corp (NASDAQ: TECH) Right Now?
Bio-Techne Corp (NASDAQ: TECH) has a price-to-earnings ratio that is above its average at 70.35x. The stock has a 36-month beta value of 1.26. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 4 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TECH is 156.91M, and at present, short sellers hold a 1.88% of that float. On September 12, 2024, the average trading volume of TECH was 977.86K shares.
TECH) stock’s latest price update
Bio-Techne Corp (NASDAQ: TECH)’s stock price has plunge by -0.39relation to previous closing price of 73.78. Nevertheless, the company has seen a 3.33% surge in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-10 that NEW ORLEANS, Sept. 10, 2024 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd. (“Oddity” or the “Company”) (NasdaqGM: ODD), if they purchased the Company’s securities between July 19, 2023 and May 20, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of New York.
Analysts’ Opinion of TECH
Many brokerage firms have already submitted their reports for TECH stocks, with Citigroup repeating the rating for TECH by listing it as a “Neutral.” The predicted price for TECH in the upcoming period, according to Citigroup is $85 based on the research report published on May 22, 2024 of the current year 2024.
Scotiabank, on the other hand, stated in their research note that they expect to see TECH reach a price target of $80. The rating they have provided for TECH stocks is “Sector Outperform” according to the report published on February 08th, 2024.
Stifel gave a rating of “Hold” to TECH, setting the target price at $65 in the report published on February 02nd of the current year.
TECH Trading at -1.65% from the 50-Day Moving Average
After a stumble in the market that brought TECH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.12% of loss for the given period.
Volatility was left at 2.95%, however, over the last 30 days, the volatility rate increased by 3.08%, as shares surge +0.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.63% upper at present.
During the last 5 trading sessions, TECH rose by +3.33%, which changed the moving average for the period of 200-days by +15.59% in comparison to the 20-day moving average, which settled at $72.72. In addition, Bio-Techne Corp saw -4.76% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TECH starting from BAUMGARTNER ROBERT V, who sale 16,000 shares at the price of $72.10 back on Aug 08 ’24. After this action, BAUMGARTNER ROBERT V now owns 43,401 shares of Bio-Techne Corp, valued at $1,153,664 using the latest closing price.
ROBERT V. BAUMGARTNER, the Director of Bio-Techne Corp, proposed sale 16,000 shares at $72.10 during a trade that took place back on Aug 08 ’24, which means that ROBERT V. BAUMGARTNER is holding shares at $1,153,664 based on the most recent closing price.
Stock Fundamentals for TECH
Current profitability levels for the company are sitting at:
- 0.21 for the present operating margin
- 0.67 for the gross margin
The net margin for Bio-Techne Corp stands at 0.15. The total capital return value is set at 0.09. Equity return is now at value 8.33, with 6.06 for asset returns.
Based on Bio-Techne Corp (TECH), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at 0.9. The debt to equity ratio resting at 0.16. The interest coverage ratio of the stock is 15.56.
Currently, EBITDA for the company is 364.76 million with net debt to EBITDA at 0.75. When we switch over and look at the enterprise to sales, we see a ratio of 10.29. The receivables turnover for the company is 4.8for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.87.
Conclusion
To sum up, Bio-Techne Corp (TECH) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
